Due to the limited efficacy of passive immunotherapeutic targeting of CD105, an active immunotherapeutic approach, as demonstrated in preclinical models of breast cancer with Listeria-based vaccines, may provide a more promising therapeutic avenue to target CD105 in mRCC (19). This evidence concerns the gene ENG and breast cancer.